Pharmacological management of autoimmune hepatitis

Bibliography

• Krawitt EL. Autoimmune hepatitis. N Engl J Med 2006;354(1):54-66
   PubMed Web of Science ®Google Scholar
• Manns MP, Czaja AJ, Gorham JD, Diagnosis and management of autoimmune hepatitis. Hepatology 2010;51(6):2193-213
   PubMedGoogle Scholar
• Kirk AP, Jain S, Pocock S, Late results of the Royal Free Hospital prospective controlled trial of prednisolone therapy in hepatitis B surface antigen negative chronic active hepatitis. Gut 1980;21(1):78-83
   PubMedGoogle Scholar
• Gregorio GV, Portmann B, Reid F, Autoimmune hepatitis in childhood: a 20-year experience. Hepatology 1997;25(3):541-7
   PubMedGoogle Scholar
• Vergani D, Mieli-Vergani G. Autoimmune hepatitis. Textbook of Hepatology: from Basic Science to Clinical Practice. 3rd edition. Blackwell Publishing, UK; 2007. p. 1089-101
   Google Scholar
• Alvarez F, Berg PA, Bianchi FB, International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999;31(5):929-38
   PubMedGoogle Scholar
• Hennes EM, Zeniya M, Czaja AJ, Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology 2008;48(1):169-76
   PubMedGoogle Scholar
• Seela S, Sheela H, Boyer JL. Autoimmune hepatitis type 1: safety and efficacy of prolonged medical therapy. Liver Int 2005;25(4):734-9
   PubMedGoogle Scholar
• Sogo T, Fujisawa T, Inui A, Intravenous methylprednisolone pulse therapy for children with autoimmune hepatitis. Hepatol Res 2006;34(3):187-92
   PubMedGoogle Scholar
• Ustundag G, Kuloglu Z, Kirsaclioglu CT, Complete regression of cirrhosis after immunosuppressive treatment in autoimmune hepatitis. Pediatr Int 2008;50(5):711-13
   PubMedGoogle Scholar
• Kerkar N, Annunziato RA, Foley L, Prospective analysis of nonadherence in autoimmune hepatitis: a common problem. J Pediatr Gastroenterol Nutr 2006;43(5):629-34
   PubMedGoogle Scholar
• Samaroo B, Samyn M, Buchanan C, Mieli-Vergani G. Long-term daily oral treatment with prednisolone in children with autoimmune liver disease does not affect final adult height. Hepatology 2006;44:438A
   Google Scholar
• Johnson PJ, McFarlane IG, Williams R. Azathioprine for long-term maintenance of remission in autoimmune hepatitis [see comments]. N Engl J Med 1995;333(15):958-63
   PubMedGoogle Scholar
• Czaja AJ, Freese DK. Diagnosis and treatment of autoimmune hepatitis. Hepatology 2002;36(2):479-97
   PubMedGoogle Scholar
• Heneghan MA, Norris SM, O'Grady JG, Management and outcome of pregnancy in autoimmune hepatitis. Gut 2001;48(1):97-102
   PubMedGoogle Scholar
• Candia L, Marquez J, Espinoza LR. Autoimmune hepatitis and pregnancy: a rheumatologist's dilemma. Semin Arthritis Rheum 2005;35(1):49-56
   PubMedGoogle Scholar
• Terrabuio DR, Abrantes-Lemos CP, Carrilho FJ, Cancado EL. Follow-up of pregnant women with autoimmune hepatitis: the disease behavior along with maternal and fetal outcomes. J Clin Gastroenterol 2009;43(4):350-6
   PubMedGoogle Scholar
• Al-Chalabi T, Boccato S, Portmann BC, Autoimmune hepatitis (AIH) in the elderly: a systematic retrospective analysis of a large group of consecutive patients with definite AIH followed at a tertiary referral centre. J Hepatol 2006;45(4):575-83
   PubMedGoogle Scholar
• Lennard L, Van Loon JA, Weinshilboum RM. Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clin Pharmacol Ther 1989;46(2):149-54
   PubMedGoogle Scholar
• Ben Ari Z, Mehta A, Lennard L, Burroughs AK. Azathioprine-induced myelosuppression due to thiopurine methyltransferase deficiency in a patient with autoimmune hepatitis. J Hepatol 1995;23(3):351-4
   PubMedGoogle Scholar
• Gisbert JP, Gomollon F, Cara C, Thiopurine methyltransferase activity in Spain: a study of 14,545 patients. Dig Dis Sci 2007;52(5):1262-9
   PubMed Web of Science ®Google Scholar
• Kaskas BA, Louis E, Hindorf U, Safe treatment of thiopurine S-methyltransferase deficient Crohn's disease patients with azathioprine. Gut 2003;52(1):140-2
   PubMedGoogle Scholar
• Czaja AJ, Carpenter HA. Thiopurine methyltransferase deficiency and azathioprine intolerance in autoimmune hepatitis. Dig Dis Sci 2006;51(5):968-75
   PubMedGoogle Scholar
• Cuffari C, Dassopoulos T, Turnbough L, Thiopurine methyltransferase activity influences clinical response to azathioprine in inflammatory bowel disease. Clin Gastroenterol Hepatol 2004;2(5):410-17
   PubMedGoogle Scholar
• Czaja AJ. Safety issues in the management of autoimmune hepatitis. Expert Opin Drug Saf 2008;7(3):319-33
   PubMedGoogle Scholar
• Wang KK, Czaja AJ, Beaver SJ, Go VL. Extrahepatic malignancy following long-term immunosuppressive therapy of severe hepatitis B surface antigen-negative chronic active hepatitis. Hepatology 1989;10(1):39-43
   PubMedGoogle Scholar
• Werner M, Almer S, Prytz H, Hepatic and extrahepatic malignancies in autoimmune hepatitis. A long-term follow-up in 473 Swedish patients. J Hepatol 2009;50(2):388-93
   PubMedGoogle Scholar
• Yeoman AD, Al-Chalabi AT, Karani JB, Evaluation of risk factors in the development of HCC in AIH: Implications for follow-up and screening. Hepatology 2008;48:863-70
   PubMed Web of Science ®Google Scholar
• Chang MH, Hadzic D, Rouassant SH, Acute and chronic hepatitis: working group report of the second World congress of pediatric gastroenterology, hepatology, and nutrition. J Pediatr Gastroenterol Nutr 2004;39(Suppl 2):S584-8
   Google Scholar
• Rumbo C, Emerick KM, Emre S, Shneider BL. Azathioprine metabolite measurements in the treatment of autoimmune hepatitis in pediatric patients: a preliminary report. J Pediatr Gastroenterol Nutr 2002;35(3):391-8
   PubMedGoogle Scholar
• Dumortier J, Arita CT, Rivet C, Long-term treatment reduction and steroids withdrawal in children with autoimmune hepatitis: a single centre experience on 55 children. Eur J Gastroenterol Hepatol 2009;21(12):1413-18
   PubMedGoogle Scholar
• Banerjee S, Rahhal R, Bishop WP. Azathioprine monotherapy for maintenance of remission in pediatric patients with autoimmune hepatitis. J Pediatr Gastroenterol Nutr 2006;43(3):353-6
   PubMedGoogle Scholar
• Cuarterolo M, Ciocca M, Velasco CC, Follow-up of children with autoimmune hepatitis treated with cyclosporine. J Pediatr Gastroenterol Nutr 2006;43(5):635-9
   PubMedGoogle Scholar
• Alvarez F, Ciocca M, Canero-Velasco C, Short-term cyclosporine induces a remission of autoimmune hepatitis in children. J Hepatol 1999;30:222-7
   PubMed Web of Science ®Google Scholar
• Debray D, Maggiore G, Girardet JP, Efficacy of cyclosporin A in children with type 2 autoimmune hepatitis. J Pediatr 1999;135(1):111-14
   PubMedGoogle Scholar
• Van Thiel DH, Carroll P, Abu-Elmagd K, Tacrolimus (FK 506), a treatment for primary sclerosing cholangitis: results of an open-label preliminary trial. Am J Gastroenterol 1995;90(3):455-9
   PubMedGoogle Scholar
• Aqel BA, Machicao V, Rosser B, Efficacy of tacrolimus in the treatment of steroid refractory autoimmune hepatitis. J Clin Gastroenterol 2004;38(9):805-9
   PubMedGoogle Scholar
• Larsen FS, Vainer B, Eefsen M, Low-dose tacrolimus ameliorates liver inflammation and fibrosis in steroid refractory autoimmune hepatitis. World J Gastroenterol 2007;13(23):3232-6
   PubMedGoogle Scholar
• Gao E, Lo D, Cheney R, Abnormal differentiation of thymocytes in mice treated with cyclosporin A. Nature 1988;336:176-9
   PubMed Web of Science ®Google Scholar
• Bucy PB, Yan Xu X, Li J, Huang GQ. Cyclosporin A-induced autoimmune disease in mice. J Immunol 1993;151:1039-50
   PubMed Web of Science ®Google Scholar
• Wu DY, Goldschneider I. Cyclosporin A-induced autologous graft-versus-host disease: a prototypical model of autoimmunity and active (dominant) tolerance coordinately induced by recent thymic emigrants. J Immunol 1999;162(11):6926-33
   PubMedGoogle Scholar
• Damoiseaux JG, van Breda Vriesman PJ. Cyclosporin A-induced autoimmunity: the result of defective de novo T- cell development. Folia Biol 1998;44(1):1-9
   PubMedGoogle Scholar
• Mieli-Vergani G, Vergani D. De novo autoimmune hepatitis after liver transplantation. J Hepatol 2004;40(1):3-7
   PubMedGoogle Scholar
• Wiegand J, Schuler A, Kanzler S, Budesonide in previously untreated autoimmune hepatitis. Liver Int 2005;25(5):927-34
   PubMedGoogle Scholar
• Czaja AJ, Carpenter HA, Lindor KD. Ursodeoxycholic acid as adjunctive therapy for problematic type 1 autoimmune hepatitis: a randomized placebo-controlled treatment trial. Hepatology 1999;30(6):1381-6
   PubMedGoogle Scholar
• Manns MP, Woynarowski M, Kreisel W, Azathioprine with budesonide induces remission more effectively than with prednisone in patients with autoimmune hepatitis. Gastroenterology 2010;139:1198-206
   Google Scholar
• Aw MM, Dhawan A, Samyn M, Mycophenolate mofetil as rescue treatment for autoimmune liver disease in children: a 5-year follow-up. J Hepatol 2009;51(1):156-60
   PubMedGoogle Scholar
• Richardson PD, James PD, Ryder SD. Mycophenolate mofetil for maintenance of remission in autoimmune hepatitis in patients resistant to or intolerant of azathioprine. J Hepatol 2000;33(3):371-5
   PubMedGoogle Scholar
• Gregorio GV, McFarlane B, Bracken P, Organ and non-organ specific autoantibody titres and IgG levels as markers of disease activity: a longitudinal study in childhood autoimmune liver disease. Autoimmunity 2002;35(8):515-19
   PubMedGoogle Scholar
• Luth S, Herkel J, Kanzler S, Serologic markers compared with liver biopsy for monitoring disease activity in autoimmune hepatitis. J Clin Gastroenterol 2008;42(8):926-30
   PubMedGoogle Scholar
• Duclos-Vallee JC, Sebagh M, Rifai K, A 10 year follow up study of patients transplanted for autoimmune hepatitis: histological recurrence precedes clinical and biochemical recurrence. Gut 2003;52(6):893-7
   PubMedGoogle Scholar
• Kerkar N, Dugan C, Rumbo C, Rapamycin successfully treats post-transplant autoimmune hepatitis. Am J Transplant 2005;5(5):1085-9
   PubMedGoogle Scholar
• Lobo-Yeo A, Alviggi L, Mieli-Vergani G, Preferential activation of helper/inducer T lymphocytes in autoimmune chronic active hepatitis. Clin Exp Immunol 1987;67(1):95-104
   PubMedGoogle Scholar
• Longhi MS, Ma Y, Mieli-Vergani G, Vergani D. Aetiopathogenesis of autoimmune hepatitis. J Autoimmun 2010;34(1):7-14
   PubMedGoogle Scholar